Cargando…

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients

Methylation of the O(6)-Methylguanine-DNA methyltransferase (MGMT) promoter is predictive for treatment response in glioblastoma patients. However, precise predictive cutoff values to distinguish “MGMT methylated” from “MGMT unmethylated” patients remain highly debated in terms of pyrosequencing (PS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radke, Josefine, Koch, Arend, Pritsch, Fabienne, Schumann, Elisa, Misch, Martin, Hempt, Claudia, Lenz, Klaus, Löbel, Franziska, Paschereit, Fabienne, Heppner, Frank L., Vajkoczy, Peter, Koll, Randi, Onken, Julia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549362/ https://www.ncbi.nlm.nih.gov/pubmed/31167648 http://dx.doi.org/10.1186/s40478-019-0745-z

Ejemplares similares

Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival
por: Onken, Julia, et al.
Publicado: (2017)

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
por: Mareike, Müller, et al.
Publicado: (2021)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
por: Incekara, Fatih, et al.
Publicado: (2020)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

Homogeneous MGMT Immunoreactivity Correlates with an Unmethylated MGMT Promoter Status in Brain Metastases of Various Solid Tumors
por: Ingold, Barbara, et al.
Publicado: (2009)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
por: Incekara, Fatih, et al.
Publicado: (2020)

Correlation of Tumor Pathology with Fluorescein Uptake and MRI Contrast-Enhancement in Stereotactic Biopsies
por: Xu, Ran, et al.
Publicado: (2022)

Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide
por: Berger, Kerstin, et al.
Publicado: (2020)

ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma
por: Maralani, Pejman Jabehdar, et al.
Publicado: (2021)

Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
por: Onken, Julia, et al.
Publicado: (2016)

Decoding molecular programs in melanoma brain metastases
por: Radke, Josefine, et al.
Publicado: (2022)

Methylation class oligosarcoma may encompass IDH-wildtype gliomas
por: Ebrahimi, Azadeh, et al.
Publicado: (2022)

PDPN contributes to constructing immunosuppressive microenvironment in IDH wildtype glioma
por: Wang, Xuya, et al.
Publicado: (2022)

Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
por: Liu, Elisa K, et al.
Publicado: (2022)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma
por: Lohkamp, Laura-Nanna, et al.
Publicado: (2016)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma
por: Saaid, Ayoub, et al.
Publicado: (2022)

GEN-13 FIREWORK PATTERN OF CANCER GENESIS FOR GLIOBLASTOMA, IDH-WILDTYPE
por: Yoon, Seon-Jin, et al.
Publicado: (2019)

Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses
por: Liu, Yu-Qing, et al.
Publicado: (2019)

Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities
por: Garrett, Matthew, et al.
Publicado: (2018)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype: case series of a new entity
por: Bender, Katja, et al.
Publicado: (2023)

Effectiveness of Immune Checkpoint Inhibition vs Chemotherapy in Combination With Radiation Therapy Among Patients With Non–Small Cell Lung Cancer and Brain Metastasis Undergoing Neurosurgical Resection
por: Wasilewski, David, et al.
Publicado: (2022)

Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma
por: Jungk, Christine, et al.
Publicado: (2019)

Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres
por: Yoon, Seon-Jin, et al.
Publicado: (2020)

Glioblastoma, IDH-wildtype: A New Association with IgM Paraproteinaemic Neuropathy?
por: Lewis, Dana M., et al.
Publicado: (2022)

Glioblastoma, IDH-wildtype with leptomeningeal metastasis to Meckel’s cave: A case report
por: Murata, Toshiki, et al.
Publicado: (2022)

Initial Treatment of IDH-Wildtype Glioblastoma in Adults Older Than 70 Years
por: Bao, Jing, et al.
Publicado: (2023)

Distribution and favorable prognostic implication of genomic EGFR alterations in IDH ‐wildtype glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Optical Characterization of Sodium Fluorescein In Vitro and Ex Vivo
por: Xu, Ran, et al.
Publicado: (2021)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions
por: Mata, Douglas A., et al.
Publicado: (2020)

MPC-02 Prognostic effects of molecular factors in elderly patients with IDH-wildtype Glioblastomas
por: Fukai, Junya, et al.
Publicado: (2020)

High-dose radiation associated with improved survival in IDH-wildtype low-grade glioma
por: Liu, Shuai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tf9mu7jmdp4gspa6tqjh06om4u